INTC vs LLY: Which Is the Better Buy?
Side-by-side comparison of Intel Corporation and Eli Lilly and Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-16.
Intel Corporation · Technology
$68.50
-13.9% upside to fair value
High Conviction
Grade D
VS
Eli Lilly and Company · Healthcare
$939.47
+71.1% upside to fair value
High Conviction
Grade A
QuantHub Verdict
LLY has more upside to fair value
(+71.1%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
INTC |
LLY |
| Current Price |
$68.50 |
$939.47 |
| Fair Value Estimate |
$59.00 |
$1,607.00 |
| Upside to Fair Value |
-13.9%
|
+71.1%
|
| Market Cap |
$343.9B |
$887.6B |
| Forward P/E |
-1245.8x
|
27.4x
|
| EV / EBITDA |
—
|
35.8x
|
| Price / Sales |
6.5x
|
14.8x
|
| Price / FCF |
-69.5x
|
107.6x
|
| Revenue Growth YoY |
+0.2%
|
+44.7%
|
| Gross Margin |
34.8%
|
83.8%
|
| Operating Margin |
-4.2%
|
45.6%
|
| Return on Equity |
-0.3%
|
77.8%
|
| Dividend Yield |
— |
0.56% |
| FCF Yield |
—
|
0.93%
|
| Analyst Consensus |
Hold
|
Strong Buy
|
Investment Thesis
Intel is a legacy semiconductor leader attempting an ambitious turnaround under new CEO Lip-Bu Tan, pivoting from a pure-play chipmaker to an integrated device manufacturer (IDM 2.0) with foundry ambitions. The business remains structurally challenged: PC market share is eroding, foundry execution is unproven, negative free cash flow persists, and margins are compressed. However, the stock trades…
Eli Lilly remains the dominant GLP-1 franchise holder with Mounjaro and Zepbound generating $36.5B combined in 2025 on 45% total revenue growth to $65.2B. The company guided $80-83B for 2026, well above prior Street consensus, and launched Foundayo (oral GLP-1, FDA approved April 2026) with $1.5B pre-built inventory. At $939 the stock trades at 14.8x P/S, right at its 5-year median, and 27.4x for…
Accumulation Zones
| Metric |
INTC |
LLY |
| Zone Low |
$44.00 |
$1,205.00 |
| Zone High |
$50.00 |
$1,366.00 |
| In Buy Zone? |
No
|
Yes
|